This year, many veterinary practices will be required to comply with the federal “Identity Theft Red Flags and Address Discrepancies Under the Fair and Accurate Credit Transactions Act of 2003,” otherwise know as the “Red Flags Rule.” A Federal Trade Commission website helps explain the rule –designed to fight identity theft – and lays out the terms under which a business would need to follow it. Under the rule, which exists on the books now but will not be enforced until May 1, businesses that qualify as “creditors” and have “covered accounts” must develop and implement identity theft prevention programs. Accepting credit cards as payment does not necessarily qualify a business as a” creditor” under the rule, but businesses that bill consumers after services are provided are considered creditors.
Animals to Be Included in Federal, Local Emergency Plans
Compounding drugs for animal patients is regulated by 50 different state boards of pharmacy and murky federal laws. Although compounded drugs are not approved by the Food and Drug Administration (FDA), they are allowed when approved drugs are not available or suitable for the intended use. Veterinarians should remember a few key things in order to stay safe and on the right side of the law. Potency, safety, efficacy and bioavailability are not guaranteedCompounding from bulk chemicals is in a “regulatory void”Compounds may only be distributed to the patient for which they were prescribedCompounding to make a cheaper version of an approved drug that already exists is illegal Use a PCAB-accredited compounding pharmacy when possible
Low-income Americans are having a hard enough time feeding themselves. Feeding their pets is an even bigger challenge. Some 42 million Americans received benefits from the Supplemental Nutrition Assistance Program (SNAP) last year.
After receiving adverse reports involving five animals, Australia-based Jurox Animal Health voluntarily recalled two lots of the widely used intravenous injectable anesthetic Alfaxan unpreserved last week, according to the US Food and Drug Administration (FDA). The reason for the recall: The presence of aluminum phosphate precipitate, which, when injected, presents a possible risk of blood vessel inflammation and formation of potentially life-threatening blood clots.
Okay, maybe just one needle every three months. But one shot every 90 days sure beats daily insulin injections, if promising new research out of Purdue University bears fruit. Last week, the school released the preliminary findings of a new study: The first minimally invasive therapy to successfully reverse Type 1 diabetes within 24 hours and maintain insulin independence for at least 90 days in test subjects.
A new study by researchers at the University of Pennsylvania’s Perelman School of Medicine and the School of Veterinary Medicine reviewed all opioids dispensed at the veterinary school for from January 2007 through December 2017. The findings show that prescriptions rose 41% annually, while the number of patient visits rose only 13%.The researchers found the ratio worrisome.
“Veterinarians who want to report suspected animal abuse often encounter a bureaucratic runaround,” says Phil Arkow. Arkow hopes that the recent launch of a free online National Directory of Abuse Investigation Agencies will help. Arkow is Coordinator of the National Link Coalition, a multidisciplinary, collaborative initiative formed in 2008 to raise awareness of the connection between animal abuse, child abuse, and domestic violence. It’s based on the idea that violence begets violence, and that when animal cruelty or neglect exists in a home, chances are that children, domestic partners, or elderly family members are being hurt, too.
The opioid shortage isn’t going away any time soon. The shortage, which is severely affecting veterinarians’ ability to provide pain management for patients, is expected to last into 2019. The primary short-term cause is a production issue at a Pfizer, Inc. plant in Kansas, but residual hurricane damage in Puerto Rico, a major pharmaceutical manufacturing center, and a pre-existing Drug Enforcement Agency mandate to reduce the manufacture of opioid medication in the United States by 20% in 2018, are also having an effect.